Victor Daniel Acuña Rocha

Dr. Victor Daniel Acuña Rocha

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in Cureus
Verified
Journal Article
Open access
PDF file
VRVictor Daniel Acuña Rocha
Victor Daniel Acuña Rocha
DRDiego Regalado-Ceballos
Diego Regalado-Ceballos
DSDaniela A. Salcedo-Soto
Daniela A. Salcedo-Soto
CRCésar A. Ramos-Delgado
César A. Ramos-Delgado
JEJorge A. Esquivel-Valerio
Jorge A. Esquivel-Valerio
DFDiana E. Flores-Alvarado
Diana E. Flores-Alvarado
Rheumatoid arthritis (RA) is a chronic inflammatory disease with a prevalence of 1%, mainly affecting women aged 25-45. It is classified by the age of onset into young-onset rheumatoid arthritis (YORA, 16-65 years) and elderly-onset rheumatoid arthritis (EORA, over 65 years), with EORA often presenting suddenly with systemic symptoms and large joint involvement due to age-related immune changes. This systematic review and meta-analysis compare the clinical and epidemiological characteristics of EORA and YORA. Observational studies were selected from PubMed, Scopus, Embase, Web of Science, and the Cochrane Central Database up to November 2023, focusing on a comparative analysis of both disease types with similar clinical progression and treatment duration limited to one month. Statistical analysis was performed in RStudio (Version 4.1.3, Posit Software, Boston, MA) using the "meta" package, applying a random effects model, inverse variance method, and Hartung-Knapp adjustment. Results for continuous variables were combined and grouped using the Cochrane formula, with medians and interquartile ranges transformed for uniformity. Four studies met the criteria. A trend was observed toward higher disease activity at diagnosis in the EORA group (mean difference (MD: 0.19, 95% CI -1.90 to 2.27), indicated by Disease Activity Score-28 (DAS28) and Simplified Disease Activity Index (SDAI) indices (MD 6.17, 95% CI -20.60 to 32.94). The EORA group also had higher Health Assessment Questionnaire (HAQ) scores (MD 0.21, 95% CI -0.03 to 0.46) and a greater number of painful (MD 1.31, 95% CI -0.86 to 3.47) and swollen joints (MD 2.35, 95% CI 0.77 to 3.92). Extra-articular manifestations, including rheumatoid nodules, lung involvement, and secondary Sjögren's syndrome, were more common in EORA patients (p < 0.004). In conclusion, the findings suggest that patients with EORA present with more intense disease activity at onset, a higher prevalence of extra-articular manifestations, greater levels of disability, and more pronounced radiographic changes. Despite these initial differences, EORA patients ultimately achieve long-term remission rates similar to those with YORA.

1 September 2020 in Human Immunology
Verified
Journal Article
Closed access
MBMónica Ballesteros-Romero
Mónica Ballesteros-Romero
RBRodrigo Barquera
Rodrigo Barquera
MRMarla Estefanía Rodríguez-López
Marla Estefanía Rodríguez-López
DHDiana Iraíz Hernández-Zaragoza
Diana Iraíz Hernández-Zaragoza
IGIsis Goné-Vázquez
Isis Goné-Vázquez
VRVictor Daniel Acuña Rocha
Victor Daniel Acuña Rocha

5 May 2024 in Cureus
Verified
Journal Article
Open access
PDF file
VRVictor Daniel Acuña Rocha
Victor Daniel Acuña Rocha
JRJosé A Ramírez-Vázquez
José A Ramírez-Vázquez
LTLuis A. González Torres
Luis A. González Torres
JLJenny C. López-Zamarrón
Jenny C. López-Zamarrón
LTLuz Del Cármen Tarín-Arzaga
Luz Del Cármen Tarín-Arzaga
Fungal rhino-orbital-cerebral infections present significant treatment challenges, especially in immunocompromised individuals, such as those with diabetes. These infections seldom occur with bacterial co-infections, which complicate their management. This report presents the case of a 74-year-old diabetic male with a long-standing history of left malar pain who experienced rhinorrhea, nasal congestion, and confusion. Diagnostic imaging revealed angioinvasive fungal sinusitis, ultimately attributed to chronic mucormycosis (CM) with concurrent Actinomyces infection, a rarely reported occurrence. We employed a comprehensive treatment strategy, which resulted in a successful recovery after 24 days. Although CM is rare, accounting for approximately 5.6% of cases with mucormycosis, it requires thorough diagnostic evaluation and prolonged treatment. The rarity of co-infections like the one we describe underscores the need for an integrated management approach. Histopathological analysis serves as the gold standard for diagnosis, with treatment typically involving surgical and extensive antifungal interventions.

31 May 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
VRVictor Daniel Acuña Rocha
Victor Daniel Acuña Rocha
JZJorge A Zuñiga-Hernández
Jorge A Zuñiga-Hernández
Victor D Acuña-Rocha, MD, Jorge A Zuñiga-Hernández, MD, MPH; Impact of Exercise Interventions on Hospitalized Patients with Community-Acquired Pneumonia: T

7 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
HGHEINNER GUIO
HEINNER GUIO
OCOmar Caceres
Omar Caceres
CSCesar Sanchez
Cesar Sanchez
CPCarlos Padilla-Rojas
Carlos Padilla-Rojas
OTOmar Trujillo
Omar Trujillo
ETEduardo Tarazona-Santos
Eduardo Tarazona-Santos
SUMMARY: The process of inhabiting the Americas by ancestral native American populations involved many individuals settling in the Peruvian Andes and Amazonian regions. Due to Latin American countries representing less than 1% of the human genome data available in public reference databases, the evolution and migration processes involved in adapting to this unique geography have not yet been fully explained. The Peruvian Genome Project is an initiative, started in 2011, to address the underrepresentation of genomic data from native South American populations. This project has collected 1,149 samples from 17 traditional native and 13 mestizo (mixed of native, African, and European ancestry) communities. Currently, 150 whole genomes and 873 array-genotyped individuals have been sequenced from across the geography of Western South America, including coastal, Andes, and Amazonian regions. We discovered 1.6 million novel genetic variants with varying frequencies, indicative of local environmental adaptations and population drift. These novel variants allow us to infer local evolutionary traits and population-specific allele frequencies for people living at different altitudes, as well as varying adaptations to pathogens and living conditions. The Peruvian Genome Project is the result of over a decade of work in sample selection, logistics, and approved regulatory community engagement, designed to enhance the human genome pool of diversity of native Americans. The data collected here enable the targeted characterization of endemic diseases, trait adaptations, and new variants of clinical significance in South America. The Peruvian Genome Project represents a step forward in international and multidisciplinary efforts to make precision medicine more inclusive and accessible for underrepresented communities in Latin America, offering significant potential for drug development and diagnostics in a neglected continent.

15 July 2024 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
VRVictor Daniel Acuña Rocha
Victor Daniel Acuña Rocha
To the Editor We read with great interest the study conducted by Schober et al, in which the objective was to assess whether rapid respiratory virus